Development of novel treatment strategies based on knowledge of cellular dysfunction in diabetes (BetaBat)

Research Areas

- Biomarker Research
  - Diagnostic
- Basic Research

At a Glance

- Status: Active Consortium
- Year Launched: 2011
- Initiating Organization: European Commission Seventh Framework Programme (FP7)
- Initiator Type: Government
- Location: Europe

Abstract

The European project BetaBat aims to develop new treatment strategies based on knowledge of cellular dysfunction in diabetes.

Mission

BetaBat will perform a detailed organelle diagnosis based on both focused and systems biology approaches, which will provide the scientific rationale for the design of specific interventions to boost the capacity of beta cells and brown adipocytes to regain homeostatic control. The project proposes that only by understanding the complex molecular mechanisms triggering cellular dysfunction in diabetes, and by integrating this knowledge at the systems level, will it be possible to develop interventional therapies that protect and restore beta cell and BAT function. The ultimate goal is to offer individual therapeutic choices based on both genetic information and organelle diagnosis.
Consortium History

The project was launched in October 2011.

Financing

BetaBat is a collaborative project funded by the European Commission under the Seventh Framework Programme.

Links/Social Media Feed

Homepage

http://betabat.ulb.ac.be/

Points of Contact

Prof. Décio L. Eizirik (coordinator)
U.L.B. CP618
Route de Lennik 808
1070 Brussels (Anderlecht)
Belgium
phone: ++32 (0)2 555 6242
e-mail: deizirik@ulb.ac.be

Sponsors & Partners

DNA Vision SA
Lund University
Medizinische Hochschule Hannover
Sanford-Burnham Medical Research Institute
Sirion Biotech
Universitat de Barcelone
Universite de Lausanne
Universite Libre de Bruxelles
University of Cambridge
VTT Technical Research Centre of Finland

Updated: 04/14/2016